Author

M. Sala

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Ecology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:metagenomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Abou-Ammoud· 1 shared A. Jabouille· 1 shared A. Pham-Ledart· 1 shared A. Uguen· 1 shared A.-A. Raymond· 1 shared B. Rousseau· 1 shared B. Vergier· 1 shared C. M. Duarte· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Abou-Ammoud

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The quality of dissolved organic matter shapes the biogeography of the active bathypelagic microbiome

M. Sebastian, P. Sanchez, G. Salazar, X. A. Alvarez-Salgado, I. Reche, X. A. G. Moran, M. Sala, C. M. Duarte, S. G. Acinas, J. M. Gasol

This study investigates the role of dissolved organic matter quality in shaping the active bathypelagic microbiome, finding that free-living prokaryotes contribute significantly in DOM-depleted regions.

bioRxiv · May 14, 2021 · PreprintEcology

Discoidin domain receptor 2 drives melanoma drug resistance through AXL-dependent phenotype switching

M. Sala, N. Allain, A. Jabouille, E. Henriet, A. Abou-Ammoud, A. Uguen, S. Di-Tommaso, D. Cyril, A.-A. Raymond, J.-W. Dupuy, E. Gerard, N. Dugot-Senant, B. Rousseau, J.-P. Merlio, A. Pham-Ledart, , F. Saltel

This study shows DDR2 drives melanoma drug resistance via AXL-dependent phenotype switching, suggesting DDR inhibition as a potential second-line treatment.

bioRxiv · Mar 26, 2021 · PreprintCancer Biology